Despite a substantial increase in treatment options, lung cancer remains the most common cause of cancer death worldwide. This represents a large unmet need, and in order to improve the situation there is ongoing intense and large-scale translational and clinical research.
While some of the biomarkers and their relevance have been known for years now, and the testing is reasonably established, there are more new, emerging biomarkers coming into clinical research, and the testing landscape is becoming complex. The increasing number of biomarkers of different alterations, and notoriously small tissue samples means effective profiling can be done only by multiple-biomarker next-generation sequencing (NGS) panels. Learn more about Oncomine Solutions
Download this guide and learn about:
- Methods for NSCLC biomarker testing and their pros/cons
- The emerging biomarkers such as RET fusions, MET exon14 skipping mutations, EGFR exon 20 insertions and ERBB2 (HER2) mutations
- How to choose the optimal NGS method for NSCLC (non-small cell lung cancer) biomarker testing in clinical research
- Emerging biomarkers in NSCLC and the most common alterations in NSCLC
* Required field